DGAP-Adhoc

aap Implantate AG: Sales by KEUR 514 and EBITDA by KEUR 450 slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties

DGAP-Ad-hoc: aap Implantate AG / Key word(s): Profit Warning/Final Results aap Implantate AG: Sales by KEUR 514 and EBITDA by KEUR 450 slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties 21-March-2017 / 14:57 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. aap Implantate AG ("aap") announces that in course of drawing up the annual financial statements for 2016 the Management Board decided as a precautionary measure to revoke an initial sale with a distribution partner invoiced in the financial year. The reason is a delayed payment of the contractual due purchase price. Rescission of the initial business results in a reduction in sales in the financial year 2016 by KEUR 757. In the continued operation in financial year 2016 sales are at EUR 10.5 million and EBITDA at EUR -7.9 million and thereby slightly below the current guidance.

Contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; [e-mail]

---

21-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	aap Implantate AG
	Lorenzweg 5
	12099 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.aap.de
ISIN:	DE0005066609
WKN:	506660
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of Announcement	DGAP News Service

556373  21-March-2017 CET/CEST